33.86
-0.99(-2.84%)
Currency In USD
Previous Close | 34.85 |
Open | 34.16 |
Day High | 35.14 |
Day Low | 33.15 |
52-Week High | 46.48 |
52-Week Low | 15.16 |
Volume | 3.58M |
Average Volume | 3.05M |
Market Cap | 5.38B |
PE | 135.44 |
EPS | 0.25 |
Moving Average 50 Days | 38.52 |
Moving Average 200 Days | 29.91 |
Change | -0.99 |
If you invested $1000 in TG Therapeutics, Inc. (TGTX) 10 years ago, it would be worth $2,208.74 as of May 09, 2025 at a share price of $33.86. Whereas If you bought $1000 worth of TG Therapeutics, Inc. (TGTX) shares 5 years ago, it would be worth $1,674.58 as of May 09, 2025 at a share price of $33.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
GlobeNewswire Inc.
Apr 30, 2025 11:30 AM GMT
Conference call to be held Monday, May 5, 2025, at 8:30 AM ETNEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss resul
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
GlobeNewswire Inc.
Apr 08, 2025 11:30 AM GMT
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Acade
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
GlobeNewswire Inc.
Apr 07, 2025 11:30 AM GMT
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experi